Please try another search
BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company’s development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson’s disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Michael Brennan | 51 | 2013 | Co-Founder & Non-Executive Director |
Francois Nader | - | 2022 | Independent Non-Executive Chairman |
Olivier Brandicourt | 68 | 2022 | Independent Non-Executive Director |
Nigel Shadbolt | - | 2022 | Independent Non-Executive Director |
Marcello Damiani | 53 | 2023 | Independent Non-Executive Director |
Susan Liautaud | - | 2022 | Independent Non-Executive Director |
John Jacob Orloff | 67 | 2022 | Independent Non-Executive Director & Workforce Non-Executive Director |
Jean Raby | 59 | 2022 | Senior Independent Non-Executive Director |
Joerg Moeller | - | 2024 | CEO & Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review